NCT01564459View on ClinicalTrials.gov

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

PHASE2CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

March 26, 2012

Primary Completion Date

April 18, 2013

Study Completion Date

April 18, 2013

Conditions

Diabetic Neuropathy, Painful

Interventions

DRUG

MK-6096

MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.

DRUG

Placebo

Matching compressed tablets, taken once daily at bedtime for 14 days.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01564459 - Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) | Biotech Hunter | Biotech Hunter